Compare

Aeglea BioTherapeutics, Inc./$SYRE

1D1W1M3M6MYTD1Y5YMAX

About Aeglea BioTherapeutics, Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Ticker
$SYRE
Sector
Health
Primary listing
NASDAQ
Employees
125
Headquarters
Waltham, United States
Website
www.spyre.com

SYRE Metrics

BasicAdvanced
$7.3B
-
-$2.01
3.03
-

What the Analysts think about SYRE

Analyst ratings (Buy, Hold, Sell) for Aeglea BioTherapeutics, Inc. stock.
Analyst projections of the future price of Aeglea BioTherapeutics, Inc. stock.

Bulls say / Bears say

All three ulcerative-colitis candidates met their primary endpoint in Phase 2 Part A, giving Spyre clinical proof-of-concept across its α4β7, TL1A and IL-23 approach. Their reported reductions in the disease activity measure were 9.2, 10.7 and 10.0 points, respectively. (SEC)
SPY002 is being developed for a proposed subcutaneous maintenance schedule every three to six months. If later studies confirm its efficacy and dosing profile, that could offer patients a more convenient option than more frequent treatment. (GlobeNewswire)
Spyre reported $1.1 billion in cash, cash equivalents and marketable securities at the end of June 2026, which it expects to fund operations into the second half of 2029. That gives it substantial time to advance its clinical programme before needing further capital. (GlobeNewswire)
The positive monotherapy findings remain preliminary: SKYLINE Part A was open-label, while the placebo-controlled combination study is still under way and its induction results are not expected until 2027. The core combination thesis therefore remains unproven. (SEC)
Although SPY072 showed some statistically significant effects in its rheumatoid arthritis study, Spyre said the results did not meet its bar to advance the drug as an RA monotherapy. That setback raises questions about the value of its wider rheumatic-disease ambitions. (GlobeNewswire, Endpoints News)
Spyre priced a $350 million common-stock offering at $85 a share, with an option for underwriters to buy up to a further $52.5 million of shares. The new shares dilute existing shareholders. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.

SYRE Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

SYRE Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing SYRE

AllUSDGBPEUR
Funds
Fund name
Fund size
$SYRE weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.49%
iShares Nasdaq US Biotechnology£BTEK
£865M0.49%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.21%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.21%
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG
€2.8B0.08%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.